



RealRate











PHARMACEUTICAL 2017



Edesa Biotech Inc. Rank 30 of 292



The relative strengths and weaknesses of Edesa Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Edesa Biotech Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Edesa Biotech Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 238%, being 235% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	12,100
Cost of Goods Sold	819
Intangible Assets	0
Liabilities, Current	624
Liabilities, Non-Current	0
Other Assets	82
Other Compr. Net Income	0
Other Expenses	316
Other Liabilities	0
Other Net Income	-111
Other Revenues	1,272
Property and Equipment	756
Research and Development	1,729
Selling, General and Administrative Expense	3,323

Output Variable	Value in 1000 USD
Assets	12,938
Liabilities	624
Expenses	6,187
Revenues	1,272
Stockholders Equity	12,314
Net Income	-5,026
Comprehensive Net Income	-5,026
Economic Capital Ratio	238%

